Autor: "Krasenbaum LJ" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: EE226 A US Claims Database Analysis of the Impact of Fremanezumab on Migraine-Related Health Care Utilization and Costs in Patients with Common Comorbidities, Acute Medication Overuse, or Difficult-to-Treat Migraine Following Prior Erenumab Use
Autorzy:: Buse, DC
Driessen, MT
Krasenbaum, LJ
Seminerio, MJ
Carr, K
Ortega, M
Packnett, E; Pokaż więcej
Źródło:: In Value in Health July 2022 25(7) Supplement:S378-S378

Czasopismo naukowe

Szczegóły

Skocz do pozycji: 2.

Tytuł:: EE19 A Retrospective US Claims Database Analysis of the Impact of Fremanezumab on Migraine-Related Health Care Utilization and Costs in Patients with Potential Acute Medication Overuse
Autorzy:: Buse, DC
Driessen, MT
Krasenbaum, LJ
Seminerio, MJ
Carr, K
Ortega, M
Packnett, E; Pokaż więcej
Źródło:: In Value in Health July 2022 25(7) Supplement:S338-S338

Czasopismo naukowe

Szczegóły

Skocz do pozycji: 3.

Tytuł:: CO114 Real-World Reductions in Acute Medication Use for Patients with Migraine Initiating Fremanezumab: A 12-Month Retrospective US Claims Analysis
Autorzy:: Krasenbaum, LJ
Driessen, MT
Seminerio, MJ
DiEgidio, R
Tian, M; Pokaż więcej
Źródło:: In Value in Health July 2022 25(7) Supplement:S325-S325

Czasopismo naukowe

Szczegóły

Skocz do pozycji: 4.

Tytuł:: EE57 Real-World Reductions in Migraine-Related Health Care Resource Utilization and Costs for Patients Initiating Fremanezumab: A 12-Month Retrospective US Claims Analysis
Autorzy:: Driessen, MT
Krasenbaum, LJ
Ramirez-Campos, V
DiEgidio, R
Tian, M
Seminerio, MJ; Pokaż więcej
Źródło:: In Value in Health July 2022 25(7) Supplement:S346-S346

Czasopismo naukowe

Szczegóły

Skocz do pozycji: 5.

Tytuł:: Real-world Impact of Fremanezumab on Migraine-Related Health Care Resource Utilization in Patients with Comorbidities, Acute Medication Overuse, and/or Unsatisfactory Prior Migraine Preventive Response.
Autorzy:: Buse DC; Department of Neurology, Albert Einstein College of Medicine, New York, NY, USA.
Krasenbaum LJ; Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA.
Seminerio MJ; Teva Branded Pharmaceuticals, Parsippany, NJ, USA.
Packnett ER; Merative, Ann Arbor, MI, USA.
Carr K; Teva Branded Pharmaceuticals, Parsippany, NJ, USA.
Ortega M; Teva Branded Pharmaceuticals, Parsippany, NJ, USA.
Driessen MT; Teva Pharmaceuticals, Piet Heinkade 107, 1019 BR, Amsterdam, Netherlands. .; Pokaż więcej
Źródło:: Pain and therapy [Pain Ther] 2024 Mar 12. Date of Electronic Publication: 2024 Mar 12.
Typ publikacji:: Journal Article

Czasopismo naukowe

Skocz do pozycji: 6.

Tytuł:: Reducing the Burden of Migraine: Safety and Efficacy of CGRP Pathway-Targeted Preventive Treatments.
Autorzy:: Nissan GR; North Texas Institute of Neurology & Headache, Plano, TX 75024, USA.
Kim R; Premier Health Clinical Neuroscience Institute and Department of Internal Medicine and Neurology, Wright State University Boonshoft School of Medicine, Dayton, OH 45409, USA.
Cohen JM; Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA 19380, USA.
Seminerio MJ; Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054, USA.
Krasenbaum LJ; Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA 19380, USA.
Carr K; Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054, USA.
Martin V; Department of Internal Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.; Pokaż więcej
Źródło:: Journal of clinical medicine [J Clin Med] 2022 Jul 27; Vol. 11 (15). Date of Electronic Publication: 2022 Jul 27.
Typ publikacji:: Journal Article; Review

Czasopismo naukowe

Informacja